Anagrelide Hydrochloride
SPD422-308
Phase 3 small_molecule completed
Quick answer
Anagrelide Hydrochloride for Essential Thrombocythemia (ET) is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Essential Thrombocythemia (ET)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed